Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00443313 · ClinicalTrials.gov registry record
Human Papillomavirus (HPV) Testing to Improve Cervical Cancer Screening in the Mississippi Delta
A clinical trial, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- 664
- Enrollment target
NCT00443313: Completed study, sponsored by National Cancer Institute (NCI).
NCT00443313 is a clinical trial that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 664 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00443313 has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- 664 participants
- Enrollment target
Study Summary
Background: * Cancer of the cervix (bottom third of the uterus, or womb) can be prevented by regular Pap tests (also called Pap smears), which check for changes in the cells of the cervix. Because many women in the United States have regular Pap smears, cervical cancer is not common in this country. However, the disease is common among women in the Mississippi Delta because of poor participation in screening programs. * The major causes of cervical cancer are persistent human papillomaviruses (HPV) infection by cancer-associated HPV types and lack of screening. These viruses cause an infection that often goes away by itself, but if it does not go away, over a long time lead to cervical cancer. HPV causes cervical abnormalities, which are detected by Pap smears and then treated. Objectives: -To determine whether an at-home self-collection method for obtaining cells from the cervix can be a simple, safe and inexpensive way to screen for cervical cancer for women who don t go to the health clinic regularly. Eligibility: * Women who reside in the counties of Leflore, Sunflower, Washington or Tallahatchie, Mississippi. * Women between 26 and 65 years of age who are not pregnant and who have not had a hysterectomy. Design: Screening study participants undergo the following: * The doctor takes a cervical sample using the same self-collection device that women will use at home to self-collect. * Pelvic examination and Pap test. For this test, the woman lies on an exam table and the doctor inserts an instrument called a speculum into the vagina, opening it to see the cervix. A special brush is used to take a few cells from the cervix. The cells are placed on a glass slide and sent to a lab for examination. * Cervical cell specimen collection using an at-home self-collection kit that participants will use at home after 2 weeks * At-home self-collection by participant after 2 weeks. * Referral to a doctor for follow-up care, if needed. * Colposcopy (see below) in all w
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 664 participants |
| Start Date | 2007-01-24 |
| Est. Completion | 2015-06-25 |
What the finished NCT00443313 record still lists
NCT00443313 is an observational study that tracks outcomes without assigning an intervention. The registered 664 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 0 interventions.
NCT00443313 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00443313 about?
NCT00443313 is a clinical study titled "Human Papillomavirus (HPV) Testing to Improve Cervical Cancer Screening in the Mississippi Delta". Background: * Cancer of the cervix (bottom third of the uterus, or womb) can be prevented by regular Pap tests (also called Pap smears), which check for changes in the cells of the cervix. Because many women in the United States have regular Pap smears, cervical cancer is not common in this country...
What is the current status of trial NCT00443313?
This trial is currently completed. The enrollment target is 664 participants. The study started on 2007-01-24. Estimated completion is 2015-06-25.
Who is sponsoring clinical trial NCT00443313?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06607341 · 664 participants · NA
Community Engagement Alliance Against Disparities
- NCT04064060 · 665 participants · Phase 3
A Study to Evaluate Long-term Safety in Participants Who Have Participated in Other Luspatercept (ACE-536) Clinical Trials
- NCT07164443 · 663 participants · Phase 3
A Study of Pasritamig Versus Placebo in Late Line Metastatic Castration-resistant Prostate Cancer (mCRPC)
- NCT06328647 · 666 participants · NA
Quantra Point-of-Care Hemostasis Monitoring
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI